Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.

ABSTRACT:

Background

SARS-CoV-2 Omicron lineages continue to evolve, driving recurrent infection waves since 2022 through immune escape in populations with diverse immunological histories. Understanding cross-variant neutralization capacity, especially against emerging variants like JN.1, is critical for optimizing protection strategies.

Methods

We conducted genomic surveillance in Jiangsu Province (December 2022-February 2024) to identify circulating variants and stratified 150 participants into six cohorts based on immune histories (BA.5/XBB breakthrough infections, JN.1 infections, and sequential exposures). Pseudovirus neutralization assays were employed to evaluate serum responses against ancestral (WT), early Omicron (BA.4/5, BF.7, BQ.1), recombinant (XBB/XBB.1.5/XBB.1.22/EG.5.1

SUBMITTER: Zhang S 

PROVIDER: S-EPMC12305720 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature